Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
about
Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.Looking to the future and learning lessons from the recent past: changing stakeholder perceptions of biosimilars in cancer.Long-Term Clinical Outcomes After Switching from Remicade(®) to Biosimilar CT-P13 in Inflammatory Bowel Disease.Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.Oral administration of ginger-derived nanolipids loaded with siRNA as a novel approach for efficient siRNA drug delivery to treat ulcerative colitis.Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.The process defines the product: what really matters in biosimilar design and production?Authors' Reply to Pires et al.: "Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes".Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel diseaseBiosimilars in paediatric inflammatory bowel diseaseNon-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies
P2860
Q38609741-143A7303-8405-4210-B441-380B1CB5AD0EQ38686396-AB655B02-DFEB-49EE-B26D-E2E0A0BE4C16Q38699157-4AFC0524-B57D-4265-88F8-B3DE0ACFB41EQ38824505-D8ABDF11-A46C-4787-8105-06DBFE211F97Q47109861-7AB294C4-BFA3-4967-B499-D08D0115B085Q47840447-C3B312F1-FC93-4ABF-B9C5-F7FF1B0DC0FCQ49979586-7B7E1F03-979F-467A-8C9B-4065650EACB2Q50115805-EE543C92-7B8A-4E15-B805-35B2F2E8C026Q55257412-B2B8AD3D-2E0E-4E0C-BACE-4222FDF43526Q57816058-34173168-D9AF-42B9-B87D-BB84C61FA549Q58707780-C479D23C-5BCA-40AF-B4F5-175C612D04B1Q58798380-419BB214-E870-406F-956B-B3054DB36827
P2860
Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Biosimilar Infliximab in Infla ...... a Managed Switching Programme.
@en
type
label
Biosimilar Infliximab in Infla ...... a Managed Switching Programme.
@en
prefLabel
Biosimilar Infliximab in Infla ...... a Managed Switching Programme.
@en
P2093
P2860
P356
P1476
Biosimilar Infliximab in Infla ...... a Managed Switching Programme.
@en
P2093
Caron Underhill
Eren Efrem
Fraser Cummings
Iftikar Ahmed
James Callaghan
Julia Wright
Louise Downey
Marion Bettey
Miles Rush
P2860
P304
P356
10.1093/ECCO-JCC/JJW216
P577
2017-01-27T00:00:00Z